Midas Letter and C-Suite are excited to announce Midas Letter LIVE. Midas Letter highlights the stocks and stories to watch in the Canadian markets today. Host James West is a recognized authority on investing in the emerging company segment having been a regularly featured guest on Business News Network, CNBC, Bloomberg, Reuters, and CTV. James West and guests provide comprehensive fundamental & technical analysis on all trending business and investment news, while interviewing the top CEOs of all public companies and analysts with the highest reputations in the business. Midas Letter is excited to feature all investing content on C-suite.

Strainprint Technologies Ltd is a medical cannabis data analytics platform. CEO Andrew Muroff explains that the company has three products on the market: a patient-focused app, a community portal, and subscription analytics. Strainprint’s patient app allows individual consumers to track their consumption of cannabis and the efficacy of the products they are using. The goal is to find the optimal cannabis profile for each consumer and recommend cannabis products to suit their needs. Strainprint also offers products for growers, retailers, researchers, and clinics, such as its analytics platform. Strainprint’s analytics allow cannabis companies and medical professionals to optimize production and treatment, and conduct better market and medical research by tracking real-time cannabis consumption and efficacy data across a broad spectrum of categories.